title: Effect of vitamin D3 administration on serum 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and osteocalcin in vitamin D-deficient elderly people.
abstract: In elderly institutionalized people, confined to bedroom and receiving no vitamin D supplementation, the frequency of vitamin D deficiency is found very high. Systematic administration of vitamin D has, therefore, been proposed to correct vitamin D deficiency. Within this context, we studied 40 elderly institutionalized subjects (mean age 80.5 + 7.2 yr) with low 25(OH)D3 concentrations (4.4 + 1.8 micrograms/l). Sixteen of them (Group I) had low serum calcium concentrations (less than 2.3 mmol/l) and 24 (Group II) had normal serum calcium concentrations (from 2.3 to 2.6 mmol/l). As hypocalcemia has been shown to regulate 1,25(OH)D3 production independent of PTH in animals and in humans, we compared their respective responses to the administration of vitamin D3. Subjects received a total dose of 15 mg (600,000 IU) of vitamin D3 divided into 3 i.m. injections at one month intervals and were explored before therapy and one and 6 months after the last dose of vitamin D3. The treatment induced a similar marked rise in 25(OH)D3 levels (from 4.1 + 1.7 to 24.4 + 8.7 micrograms/l for group I and from 5.1 + 1.8 to 27.2 + 8.0 micrograms/l for group II) in both groups but increased the 1,25(OH)2D3 concentrations only in group I (from 22.9 + 6.9 to 32.6 + 11.3 ng/l). Meanwhile serum calcium concentrations rose in group I (to low normal range i.e. 2.31 + 0.07 mmol/l) and were unaffected in group II. These results suggest that hypocalcemia is a potent stimulator of renal 1-hydroxylase in elderly people. Furthermore, a transient significant (P less than 0.01) increase in serum osteocalcin (from 10.6 + 4.1 to 14.1 + 5.9 micrograms/l) could be observed in group I which demonstrates for the first time that the osteocalcin response of osteoblasts to stimulation by 1,25(OH)2D3 is retained in very old people.
authors.affiliation: Laboratoire de Biochimie, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Guillemant
authors.forename: J
authors.initials: J
authors.lastname: Guillemant
authors.forename: D
authors.initials: D
authors.lastname: Feteanu
authors.forename: R
authors.initials: R
authors.lastname: Sebag-Lanoé
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002112:Calcifediol / Q000097:blood*; D002118:Calcium / Q000097:blood; D002762:Cholecalciferol / Q000008:administration & dosage* / Q000627:therapeutic use; D004100:Dihydroxycholecalciferols / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D015675:Osteocalcin / Q000097:blood*; D014808:Vitamin D Deficiency / Q000097:blood / Q000188:drug therapy*
chemical_list: D004100:Dihydroxycholecalciferols; D015675:Osteocalcin; D002762:Cholecalciferol; D002112:Calcifediol; D002118:Calcium